Skip to main content

Table 1 Mutation analysis in the cohort of LEN patients

From: Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide

Case Response TET2 UTX CBL EZH2 ASXL1 TP53 N-RAS K-RAS IDH1 IDH2 DNMT3A
1 CR WT WT WT WT WT WT WT WT WT WT WT
2 CR WT WT WT WT L775fsX1 WT WT WT WT WT WT
3 PR WT WT WT WT WT WT WT WT WT WT WT
4 NR WT WT WT WT WT WT WT WT WT WT WT
5 CR WT WT WT WT E1102D WT WT WT WT WT R882H
6 PR P1681fsX2 WT WT WT P1277fsX2 WT WT WT WT WT WT
7 CR WT WT WT WT WT WT WT WT WT WT WT
8 HI WT WT WT WT WT WT WT WT WT WT WT
10 CR WT WT WT WT WT WT WT WT WT WT WT
11 HI WT WT WT WT WT WT WT L19F WT WT WT
12 CR V1417F WT WT WT WT WT WT WT WT WT WT
13 NR WT WT WT WT WT WT WT WT WT WT WT
14 PR WT WT WT WT WT WT WT WT WT WT WT
15 CR T1978P WT WT WT WT WT WT WT WT WT WT
16 NR WT WT WT WT S846N WT WT WT WT WT WT
17 NR N1068fsX13 WT WT WT WT WT WT WT WT WT WT
18 NR WT WT WT WT WT WT WT WT WT WT WT
19 NR P1962L WT WT WT WT WT WT WT WT WT WT
20 CR WT WT WT WT WT WT WT WT WT WT R882H
21 HI WT WT WT T726X WT WT WT WT WT WT WT
22 HI WT WT WT WT WT WT WT WT WT WT WT
  1. Abbreviation: CR complete response; PR partial response; HI hematologic improvement; WT wild type